Viewing data from:

QUININE SULFATE

ANDA

QUININE SULFATE | A091661 | TEVA PHARMACEUTICALS USA

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Quinine Sulfate (2023)

Total Spending

$410K

Total Claims

3,157

Beneficiaries

1,138

Avg Cost/Unit

$2.05

Spending Trend

$1.2M(2019)→$813K(2020)→$699K(2021)→$543K(2022)→$410K(2023)

YoY Change:-9.5%

5yr CAGR:-7.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF4 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

SHIVA INTERNATIONALQUININE SULFATE USP

DMF 240632010

DSM MINERA BVInactiveQUININE SULFATE USP XIX/ NF XII

DMF 33981978

BOEHRINGER MANNHEIM GMBHInactiveQUININE SULFATE

DMF 94621991

PT SINKONA INDONESIA LESTARIInactiveQUININE SULFATE USP

DMF 199052006

PT KIMIA FARMA PERSERO TBKInactiveQUININE SULFATE

DMF 209512007

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 324MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Sep 28, 2012

No patent or exclusivity listings for this strength.